Terrence W. Norchi, MD, our co-founder, serves as our President and Chief Executive Officer, and he is a director on our Board of Directors.  Dr. Norchi has served in similar positions since co-founding ABS, our predecessor company in 2006. Prior to ABS, Dr. Norchi was portfolio manager of one of the world’s largest healthcare mutual funds and pharmaceutical analyst at Putnam Investments. Prior to that he served as the senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management, and as a sell-side analyst covering non-U.S. pharmaceutical equities at Sanford C. Bernstein in New York City.

Dr. Norchi earned an M.B.A. from the Massachusetts Institute of Technology, Sloan School of Management in 1996. Dr. Norchi earned an M.D. degree in 1990 from Northeast Ohio Medical University and completed his internal medicine residency in 1994 at Baystate Medical Center, Tufts University School of Medicine, where he was selected to serve as the Chief Medical Resident.

Dr. Norchi brings to our Board of Directors and management team invaluable experience and knowledge of our core technology and proposed product candidates as a result of his first-hand experience with the development of that technology, having ushered it from the research laboratory to its current stage of development. He is a primary inventor on many of our patents. His investing experience as a former public company analyst and a portfolio manager provides further insights and value as the company advances toward commercialization.

Dr. Norchi serves on the Board of Advisors of the Boston Museum of Science. 

Mr. Abrams has over 25 years of experience as a Chief Financial Officer to numerous public and private companies; principal investor; investment banker; merchant banker; strategic and financial advisor; and Board member. Mr. Abrams’ capabilities span a broad range of activities with a particular expertise in the areas of operational management, complex financial engineering, financial advisory, and capital markets strategy primarily for companies in the technology and healthcare sectors. Mr. Abrams graduated with an MBA with Honors from the Booth School of Business at the University of Chicago and received his BBA with Honors from the University of Massachusetts at Amherst as a William F. Field Alumni scholar, an award given annually to the top finance student in the class.

Mr. Carlson joined Arch Therapeutics as Director of Sales in 2021 and was promoted to Vice President of Sales in December, 2023. He has over 20 years of medical device leadership experience with a track record of driving commercial growth within wound care, trauma, and dermatology. Prior to joining Arch, Mr. Carlson was an Area Vice President and Director of Sales at Z-Medica (now Teleflex), where he helped bring QuikClot® to the US healthcare market and drove revenue expansion in multiple selling channels. Prior to that, he was a Territory Manager at Smith & Nephew with responsibility for Advanced Wound Care Products. Mr. Carlson graduated from West Virginia University with a BS in Sports Management. 

Mr. Dhillon was appointed as a member of our Board of Directors in July 2018. Mr. Dhillon currently serves as the Chair of the Board and Chief Executive Officer of Skye Bioscience, Inc. He is also currently a board member of Emerald Health Pharmaceuticals, Inc. and Emerald Health Therapeutics, Inc. (CSE: EMH), a Canadian Securities Exchange listed company.

Mr. Dhillon was previously a Co-founder and Director of OncoSec Medical Incorporated (NASDAQ: ONCS) and was formerly the CEO of OncoSec through March 2018. Prior to OncoSec, Mr. Dhillon was the Vice President of Finance and Operations at Inovio Pharmaceuticals, Inc. (NASDAQ: INO) from September 2003 until March 2011. Mr. Dhillon has previously been a consultant and board member for several TSX Venture Exchange-listed early-stage life science companies, which matured through advances in their development pipelines and subsequent M&A transactions. Prior to joining Inovio, Mr. Dhillon worked for a corporate finance law firm as a law clerk and worked with MDS Capital Corp. (now Lumira Capital Corp.). Mr. Dhillon is an active member of his community and places great value on helping future leaders overcome challenges through mentorship and education. He is a co-founder and board member of Young Entrepreneurship Leadership Launchpad (YELL), a not-for-profit and charity organization in Canada.

Mr. Dhillon has a Bachelor of Arts with honors in Political Science and a minor in Business Administration from Simon Fraser University.

We believe Mr. Dhillon’s experience in the biotechnology and pharmaceutical industry and his experience with publicly traded companies give him the qualifications necessary to serve as a director of the Company. 

Larry Hicks, an advisor to Arch, brings over 30 years of experience in medical devices. He started in field sales for ACMI, an endoscopy market leader, and subsequently joined Karl Storz Endoscopy and eventually led US Sales and Operations. In 2004, he rejoined ACMI to help lead a sales process (19x EBITDA in 2005) and then served as its President and CEO within Gyrus Group. Mr. Hicks returned to private equity as President & CEO of NeuroTherm (a Cortec Company), which he transformed from $10m revenue and 10 employees into a vertically integrated $50m Company with offices in Boston, London, Amsterdam and Dusseldorf. NeuroTherm was sold for a 5x return on invested capital in 5 years (noteworthy during the ‘07-‘12 economic period).

Mr. Hicks then spent two and a half years acquiring and integrating Z-MEDICA (maker of Combat Gauze Products) into the portfolio of DWHP, a private equity company with whom he is a Limited Partner and advisor in Funds II-V and for whom he has served on various Boards. Z-Medica was acquired by Linden Capital Partners (6x return of capital to investors).

Mr. Hicks is currently the CEO of Healthcare Components Group, a global manufacturer of OEM and replacement parts used for the manufacture and repair of medical devices. He also serves as the Managing Partner at Drake Partners, LLC a boutique healthcare co-investment and operating company. Mr. Hicks received a BA from Fairfield University.

Mr. Hicks is an experienced executive, director, and investor in the healthcare, biotech, and medical device sectors with a successful track record of building sales organizations and orchestrating merger and acquisition transactions that returned substantial value to shareholders.  We believe that these elements of his background qualify him to add value as a director of Arch. 

Dr. Fish joined our Board of Directors in January 2022.  With over 30 years of experience in health care, life sciences, and biotechnology, Dr. Fish has a particular interest in cost-reducing strategies utilizing value-based reimbursement models. Dr. Fish is currently the CEO of the Greater Lawrence Family Health Centers, a nationally recognized Federally Qualified Health Center operating 9 clinical sites serving 70,000 patients. 

Previously, Dr. Fish was CEO of Cellanyx, a cancer diagnostic company saving patients unnecessary surgery and complications by differentiating aggressive from indolent tumors. He has also worked as VP of Business Development at International Collagenesis, a tissue-engineering firm, as a securities analyst in the medical devices sector for Sanford Bernstein, as a healthcare consultant at The Boston Consulting Group, and as a solo practice physician. Dr. Fish is a Trustee Advisor of Beth Israel Deaconess Medical Center in Boston, where he previously chaired the Patient Care Committee and holds membership on the Patient Care Assessment and Quality Committee, and Medical Education Committee. He has served as Chairman of the Licensing Board for Dubai Health Care, as well as the Licensing Committee for the Board of Registration in Medicine for the Commonwealth of Massachusetts. Dr. Fish is currently a member of the Board of Directors of Etiometry and of the Altarum Institute. 

Dr. Fish is Board Certified in Internal Medicine, holds an MBA from the Yale School of Management, an MD from the Yale School of Medicine, and a bachelor's degree in biochemistry from Harvard University. 

Dr. Fish is a medical doctor with substantial capital markets experience.  We believe his leadership endeavors as an investor, board member, and/or senior executive of numerous innovative medical device companies and other healthcare organizations, enable him to add perspective and value as a member of the board.